ATE458485T1 - Ubiquitin-ligase-hemmer und verwandte verfahren - Google Patents

Ubiquitin-ligase-hemmer und verwandte verfahren

Info

Publication number
ATE458485T1
ATE458485T1 AT04777768T AT04777768T ATE458485T1 AT E458485 T1 ATE458485 T1 AT E458485T1 AT 04777768 T AT04777768 T AT 04777768T AT 04777768 T AT04777768 T AT 04777768T AT E458485 T1 ATE458485 T1 AT E458485T1
Authority
AT
Austria
Prior art keywords
ubiquitin ligase
related methods
compounds
ligase inhibitors
inhibitors
Prior art date
Application number
AT04777768T
Other languages
English (en)
Inventor
Iris Alroy
Shmuel Tuvia
Yuval Reiss
Ofra Levi-Hacham
Original Assignee
Proteologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/035712 external-priority patent/WO2004098492A2/en
Priority claimed from PCT/US2004/006308 external-priority patent/WO2004078130A2/en
Priority claimed from PCT/US2004/006619 external-priority patent/WO2004099388A2/en
Priority claimed from PCT/US2004/010582 external-priority patent/WO2004089302A2/en
Priority claimed from PCT/US2004/016865 external-priority patent/WO2005001485A2/en
Application filed by Proteologics Inc filed Critical Proteologics Inc
Application granted granted Critical
Publication of ATE458485T1 publication Critical patent/ATE458485T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AT04777768T 2003-07-11 2004-07-09 Ubiquitin-ligase-hemmer und verwandte verfahren ATE458485T1 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US48673003P 2003-07-11 2003-07-11
US48979503P 2003-07-24 2003-07-24
PCT/US2003/035712 WO2004098492A2 (en) 2002-11-11 2003-11-10 Trans-golgi network-associated processes, methods and compositions related thereto
US54989604P 2004-03-02 2004-03-02
PCT/US2004/006308 WO2004078130A2 (en) 2003-03-03 2004-03-02 Posh interacting proteins and related methods
PCT/US2004/006619 WO2004099388A2 (en) 2003-03-05 2004-03-05 Cbl-b polypeptides, complexes and related methods
PCT/US2004/010582 WO2004089302A2 (en) 2003-04-03 2004-04-05 Posh polypeptides, complexes and related methods
PCT/US2004/016865 WO2005001485A2 (en) 2003-05-30 2004-05-28 Pem-3-like compositions and related methods thereof
PCT/US2004/021900 WO2005007141A2 (en) 2003-07-11 2004-07-09 Ubiquitin ligase inhibitors and methods related thereto

Publications (1)

Publication Number Publication Date
ATE458485T1 true ATE458485T1 (de) 2010-03-15

Family

ID=41795377

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04777768T ATE458485T1 (de) 2003-07-11 2004-07-09 Ubiquitin-ligase-hemmer und verwandte verfahren

Country Status (5)

Country Link
US (1) US7659277B2 (de)
EP (1) EP1651226B1 (de)
AT (1) ATE458485T1 (de)
DE (1) DE602004025708D1 (de)
WO (1) WO2005007141A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ543804A (en) * 2003-05-30 2009-09-25 Proteologics Inc Pem-3-like compositions and related methods thereof
WO2005076695A2 (en) * 2004-02-11 2005-08-25 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
FI20041129A0 (fi) * 2004-08-30 2004-08-30 Ctt Cancer Targeting Tech Oy Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
US20090312352A1 (en) * 2004-10-21 2009-12-17 Tomas Mikael Mustelin Compositions and methods for treatment of disease caused by yersinia spp infection
EP1820024B1 (de) * 2004-12-01 2012-06-13 Proteologics, Ltd Ubiquitin-ligase-assays und verwandte reagenzien
ITMI20042475A1 (it) * 2004-12-23 2005-03-23 Cell Therapeutics Europe Srl Uso di derivati tiazolidinonici come agenti terapeutici
CA2619153C (en) * 2005-01-21 2013-12-31 President And Fellows Of Harvard College Regulation of protein synthesis by inhibition of eif4e-eif4g interaction
JP2008543836A (ja) * 2005-06-15 2008-12-04 ニューヨーク ブラッド センター 複素環置換フェニルフランおよび関連化合物を含む抗ウイルス組成物
WO2007088531A2 (en) * 2006-02-02 2007-08-09 Proteologics Ltd. Pem-3-like polypeptides, complexes, and related methods
DE102006008321A1 (de) * 2006-02-17 2007-08-30 Virologik Gmbh Mittel zur Behandlung von Infektionen mit Influenzaviren
JP5543209B2 (ja) * 2006-10-30 2014-07-09 ヒブリジェニクス・エスアー 新規のシステインプロテアーゼのテトラサイクリン阻害剤、その薬剤組成物および治療のためのその使用
EP2591675A1 (de) * 2006-11-27 2013-05-15 H. Lundbeck A/S Heteroarylamidderivate
US7915245B2 (en) 2007-02-01 2011-03-29 The Board Of Regents Of The University Of Texas System Methods and compositions of trail-death receptor agonists/activators
WO2008100913A2 (en) * 2007-02-12 2008-08-21 The Johns Hopkins University Early detection and prognosis of colon cancers
WO2008099022A1 (en) * 2007-02-16 2008-08-21 Tibotec Pharmaceuticals Ltd. 10-sulfonyl-dibenzodiazepinones useful as hepatitis c virus inhibitors
EP2190432A2 (de) * 2007-08-22 2010-06-02 Protelogiecs, Ltd. Pyrimidin- und pyridin-derivate als posh- und posh-ap-hemmer
DE102007040336A1 (de) * 2007-08-27 2009-03-05 Johann Wolfgang Goethe-Universität Frankfurt am Main Neue Inhibitoren der 5-Lipoxygenase und deren Verwendungen
AT506041A1 (de) * 2007-12-10 2009-05-15 Univ Innsbruck Verfahren zur erhöhung der immunreaktivität
JP4748823B2 (ja) * 2009-02-12 2011-08-17 株式会社ファルマデザイン カゼインキナーゼ１δ及びカゼインキナーゼ１ε阻害剤
EP2509601A4 (de) * 2009-11-30 2013-05-29 Proteologics Ltd Kleine pyrimidinderivate und verwendungsverfahren dafür
EP2555764A1 (de) * 2010-04-09 2013-02-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antimikrobielle verbindungen von 1,4-naphtochinonstruktur
US9073941B2 (en) 2010-06-28 2015-07-07 Academia Sinica Compounds and methods for treating tuberculosis infection
HUE044867T2 (hu) * 2011-05-12 2019-11-28 Proteostasis Therapeutics Inc Proteosztázis szabályzók
WO2014179785A1 (en) * 2013-05-03 2014-11-06 Inscent, Inc. Improved honeybee repellents and uses thereof
AR110456A1 (es) * 2016-01-13 2019-04-03 Bayer Cropscience Ag Uso de sustancias activas para controlar infecciones por virus en plantas
WO2018085208A1 (en) 2016-11-02 2018-05-11 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting tsg101-ubiquitin interaction
IL312367A (en) * 2017-01-31 2024-06-01 Arvinas Operations Inc Cereblon ligands and bifunctional compounds comprising the same
KR102459858B1 (ko) * 2019-04-02 2022-10-27 연세대학교 산학협력단 신규 화합물 및 이를 유효성분으로 포함하는 호흡기 질환의 예방 또는 치료용 조성물
AU2020405129A1 (en) 2019-12-19 2022-06-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN114592006A (zh) * 2022-04-29 2022-06-07 昆明理工大学 Memo1基因的新用途
KR20240154714A (ko) * 2023-04-18 2024-10-28 주식회사 넷타겟 Setdb1 억제 활성을 갖는 신규한 화합물 및 이의 용도

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL251189A (de) * 1959-05-07
JPS6253963A (ja) * 1985-08-31 1987-03-09 Taisho Pharmaceut Co Ltd 肝疾患治療剤
WO2000010573A1 (en) * 1998-08-21 2000-03-02 Viropharma Incorporated Compounds, compositions and methods for treating or preventing viral infections and associated diseases
CN1288667A (zh) * 1999-09-21 2001-03-28 马越 乙霉威·多菌灵杀菌组合物
US20040009613A1 (en) * 2001-02-16 2004-01-15 Ming-Ming Zhou Methods of identifying modulators of bromodomains
US6727267B2 (en) * 2000-04-05 2004-04-27 Tularik Inc. NS5B HVC polymerase inhibitors
AU2001240021A1 (en) * 2000-04-13 2001-10-30 Millennium Pharmaceuticals, Inc. Diazafluorenone il-8 receptor antagonists
GB0013655D0 (en) * 2000-06-05 2000-07-26 Prolifix Ltd Therapeutic compounds
WO2002062337A1 (en) * 2000-12-18 2002-08-15 Smithkline Beecham Corporation Thiazolidinediones
HUP0303418A3 (en) * 2000-12-18 2007-05-02 Boehringer Ingelheim Ca Ltd Inhibitors of papilloma virus
GB2376943B (en) * 2001-05-18 2005-03-16 Pantherix Ltd Compounds and their therapeutic use
EP1310552B1 (de) 2001-11-09 2007-06-13 Proteologics, Inc. Posh Nukleinsäure, Polypeptide und darauf bezogene Verfahren
WO2004098492A2 (en) * 2002-11-11 2004-11-18 Proteologics, Inc. Trans-golgi network-associated processes, methods and compositions related thereto
FR2833949B1 (fr) * 2001-12-21 2005-08-05 Galderma Res & Dev NOUVEAUX LIGANDS ACTIVATEURS DES RECEPTEURS PPARy, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION EN MEDECINE HUMAINE AINSI QU'EN COSMETIQUE
US20050049267A1 (en) * 2002-03-01 2005-03-03 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
WO2003103686A1 (en) * 2002-06-06 2003-12-18 Smithkline Beecham Corporation Thrombopoietin mimetics
JP4782564B2 (ja) * 2002-07-10 2011-09-28 メルク セローノ ソシエテ アノニム アゾリジノン−ビニル縮合−ベンゼン誘導体
EP1389461A1 (de) * 2002-08-14 2004-02-18 Axxima Pharmaceuticals Aktiengesellschaft Pyrimidone mit antiviralen Eigenschaften
EP1646644A4 (de) * 2003-03-03 2007-05-16 Proteologics Inc Mit posh wechselwirkende proteine und entsprechende verfahren
WO2004089302A2 (en) * 2003-04-03 2004-10-21 Proteologics, Inc. Posh polypeptides, complexes and related methods

Also Published As

Publication number Publication date
EP1651226B1 (de) 2010-02-24
WO2005007141A3 (en) 2005-03-24
EP1651226A2 (de) 2006-05-03
US7659277B2 (en) 2010-02-09
WO2005007141A2 (en) 2005-01-27
US20070015768A1 (en) 2007-01-18
DE602004025708D1 (de) 2010-04-08

Similar Documents

Publication Publication Date Title
ATE458485T1 (de) Ubiquitin-ligase-hemmer und verwandte verfahren
WO2006028958A3 (en) Pyridyl inhibitors of hedgehog signalling
ATE523196T1 (de) Mitotische kinesinhemmer und verfahren zu ihrer verwendung
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
EP1481077A4 (de) Mitotische kinesin-hemmer
GEP20084420B (en) Use of imidazole compounds for the treatment of neurodegenerative disorders
TW200510416A (en) P38 inhibitors and methods of use thereof
EP1463733A4 (de) Inhibitoren von mitotischem kinesin
TW200604192A (en) Compounds and methods for inhibiting mitotic progression
WO2004058700A3 (en) Mitotic kinesin inhibitors
ATE424388T1 (de) Mitotische kinesinhemmer
WO2004058148A3 (en) Mitotic kinesin inhibitors
MX2007004276A (es) 1,5-naftiridin-azolidinonas que tienen actividad antiproliferativa de cdk-1.
LTC2805723I2 (lt) Kladribino režimas, skirtas išsėtinei sklerozei gydyti
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
MX2009006885A (es) Derivados de pirrolo[3,2-a]piridina para inhibir la actividad de la proteina cinesina del huso.
WO2005074375A3 (en) Heparanase inhibitors and uses thereof
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
WO2002060375A3 (en) Diphenyl ether derivatives and their uses as heparanase inhibitors
DE60329326D1 (de) Tace inhibitoren
WO2007120333A3 (en) Tetracyclic kinase inhibitors
WO2004060878A3 (en) Inhibitors of phosphatases
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
BRPI0615141A2 (pt) inibidores pentacìclicos de quinase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties